Commercial Entrepreneurial Validation, page-37

In may the company announced it's agreement with Acpeth that we all know about, whilst this article hasn't been updated for some time it does state that the study is set to be completed in October 2016 by Acpeth
https://clinicaltrials.gov/ct2/show/NCT02008539?term=apceth&rank=1

MSC are being used in this trail which are said to be Agenmestencel-T. This is Acpeth first genetically modified MSC although the one's used in this test are "patients own" if there are positive results from the trials it could lead to further development of MSC using Cynata's cymerus technology. The announcement in May said we could expect collaboration toward the end of 2016. The Acpeth website states these trails are already in process.

So to break it down for those who don't understand. Acpeth is currently conducting trials using patients own cells, the same one's which Cynata can re-produce. If these trails turn a positive result, I am looking forward to what deal can be made with the 2 companies. I will try and keep an eye out for the results of the trials but it seems as though they are almost complete. Just a bit of hope for all those holders